Company news
Bioasis Technologies Inc. (OTC:BIOAF) news
Bioasis Technologies Inc. news releases on 6ix. Latest, Jun 20, 2023: Bioasis Provides Corporate Update and Announces Suspension of Operations
Press releases & updates
Bioasis Provides Corporate Update and Announces Suspension of Operations
June 19, 2023
Bioasis Provides Update on Business Operations
March 22, 2023
Bioasis Announces AGM Results and Provides Update on Financial Position
February 3, 2023
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
January 23, 2023
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
January 19, 2023
Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders
January 11, 2023
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
December 19, 2022
Bioasis Technologies Inc. Announces Shareholder Webinar
December 13, 2022
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
December 13, 2022
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022
October 28, 2022
Bioasis Technologies Inc. Announces Stock Option Grants
August 8, 2022
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
July 29, 2022
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
June 16, 2022
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
June 14, 2022
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
May 10, 2022
Bioasis Enters Into Research Collaboration With Janssen
April 11, 2022
Bioasis to Attend and Present at Upcoming Industry Conference
March 9, 2022
Bioasis Announces $200,000 Non-Brokered Private Placement
February 17, 2022
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021
January 20, 2022
Bioasis Announces Annual General Meeting Results
December 16, 2021
Bioasis to Attend and Present at Upcoming Industry Conferences
December 9, 2021
Bioasis Announces Annual General Meeting Details
November 29, 2021
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021
October 28, 2021
Bioasis to Attend Upcoming Industry Conferences
September 30, 2021
Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor
August 18, 2021
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase
August 9, 2021
Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager
July 20, 2021
Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis
July 7, 2021
Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer
July 1, 2021
Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration
June 30, 2021
Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners
June 29, 2021
Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million
June 21, 2021
Bioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS Therapeutics
June 3, 2021
Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration
March 31, 2021
Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology
March 29, 2021
Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing
March 24, 2021
Bioasis Technologies Inc. Announces Warrant Extension and Repricing
March 22, 2021
Bioasis to Attend and Present at Upcoming Investor and Industry Conferences
March 8, 2021
Bioasis Announces Shares for Debt Transaction
February 9, 2021
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020
January 27, 2021
Bioasis Announces Stock Option Grant
January 22, 2021
Bioasis to Present at Upcoming Industry Conferences
January 4, 2021
Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation
November 3, 2020
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance
November 3, 2020
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020
October 29, 2020
Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research
October 22, 2020
Bioasis Announces Issuance of US Patent Relating to xB³™ Platform Technology for The Delivery of Therapeutic Agents Across the Blood-Brain Barrier
October 20, 2020
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020
July 27, 2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
July 9, 2020
Bioasis Announces Stock Option Grants
July 7, 2020